<DOC>
	<DOCNO>NCT00285467</DOCNO>
	<brief_summary>The majority patient moderate severe chronic kidney disease ( CKD ) ( stag 3 4 ) develop secondary hyperparathyroidism ( 2°HPT ) , optimal therapy control hyperparathyroidism group unknown . The National Kidney Foundation present guideline 2003 recommend vitamin D supplementation vitamin D insufficient patient active vitamin D therapy patient sufficient level . These guideline base opinion since significant trial determine vitamin D supplementation effective population . The active vitamin D metabolites doxercalciferol , paricalcitol , calcitriol show effectively suppress parathyroid hormone ( PTH ) , compare vitamin D supplementation calciferol ( ergocalciferol cholecalciferol ) . Beyond hyperparathyroidism , small study suggest vitamin D replacement vitamin D insufficient non-CKD subject result improve pain , feel well , blood pressure strength . In propose study wish directly compare effectiveness cholecalciferol versus doxercalciferol suppress elevate PTH level subject CKD dialysis vitamin D insufficiency three month study . Secondary endpoint change blood pressure .</brief_summary>
	<brief_title>Cholecalciferol Versus Doxercalciferol Treatment Secondary Hyperparathyroidism Chronic Kidney Disease</brief_title>
	<detailed_description>Patients CKD stage 3 randomly allocate ( blind group allocation ) either cholecalciferol ( 4000 U per day one month 2000 IU daily thereafter ) doxercalciferol ( 2.5 mcg po daily . Assessments blood endpoint ( primary end point PTH ; secondary calcium , phosphorus ) do monthly . Other assessment ( blood pressure ) do baseline 3 month .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Renal Osteodystrophy</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>age 18 year old old , male female able sign inform consent CKD stage 3 ( GFR 3059 ml/min ) stage 4 ( 1529 ml/min ) intact Parathyroid hormone level ( iPTH ) &gt; 100 pg/ml stage 3 iPTH &gt; 150 pg/ml stage 4 calcidiol level ≤ 20 ng/ml ability ambulate without assistance intact PTH &gt; 400 pg/ml initial correct Calcium &gt; 9.7 mg/dl initial serum Phosphorous &gt; 5.0 mg/dl initial standardize blood pressure &gt; 160/100 history significant liver disease cirrhosis anticipate requirement dialysis 6 month malabsorption , severe chronic diarrhea , ileostomy calcimimetic active vitamin D therapy 30 day prior enrollment use digoxin , magnesium containing product , mineral oil , cholestyramine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>kidney , parathyroid hormone , vitamin</keyword>
</DOC>